Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation

The S.Korean company intends to be reviewed sequentially following the receipt of data from clinical stages 1 and 2a

Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation
Ji-Hyun Lee 1
2023-03-16 15:58:19 bluesky@hankyung.com
Bio & Pharma

Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistamab), has received fast-track designation from the US Food and Drug Administration.

This designation enables clinical development and application preparation for approval to proceed simultaneously, thereby shortening the time required for commercialization.

The company intends to be reviewed sequentially following the receipt of data from clinical stages 1 and 2a, which are currently underway in Europe and the US.

PBP1510 is a novel antibody drug that targets a protein found in pancreatic cancer. In 2020, it was granted orphan drug designation by both the US FDA and the Korean Ministry of Food and Drug Safety.

Write to Ji-Hyun Lee at bluesky@hankyung.com
#Prestige Biopharma #pancreatic cancer antibody drug #PBP1510 #Ulenistamab #korea prestige biopharma #prestige biopharma fda

Prestige Bio's Herceptin biosimilar proves equivalence in clinical trials

Prestige Bio's Herceptin biosimilar proves equivalence in clinical trials

Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer biosimilar (biopharmaceutical generic drug) HD201 proved its equivalence to the original drug Herceptin.HD201 is Prestige Biopharma's first biosi

Prestige Biopharma submits clinical trial plan in Australia

Prestige Biopharma submits clinical trial plan in Australia

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US,  has applied to the Australian clinical trial review committee for its phase 1 and 2a clinical trial plan of its new pancreatic cancer drug PBP1510 (ulenistamab).The company speciali

Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. The patent name is “Novel CTHRC1's specific antibody and use thereof."Following the PAUF (pancreatic adenocarcinoma up-regulated factor) neu
(* comment hide *}